{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:18:25Z","timestamp":1793067505308,"version":"4.5.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Mucopolysaccharidosis type IIIB syndrome (Sanfilippo disease) is a rare autosomic recessif disorder caused by mutations in the \u03b1-N-acetylglucosaminidase (NAGLU) gene coding for a lysosomal enzyme, leading to neurodegeneration and progressive deterioration of cognitive abilities in affected children. To supply the missing enzyme, several recent human gene therapy trials relied on the deposit of adeno-associated virus (AAV) vectors directly into the brain. We reported safety and efficacy of an intracerebral therapy in a phase 1\/2 clinical trial (<jats:uri>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03300453<\/jats:uri>), with a recombinant AAV serotype 2\/5 (rAAV2\/5) coding human NAGLU in four children with MPS IIIB syndrome receiving immunosuppression. It was reported that AAV-mediated gene therapies might elicit a strong host immune response resulting in decreased transgene expression. To address this issue, we performed a comprehensive analysis of cellular immunity and cytokine patterns generated against the therapeutic enzyme in the four treated children over 5.5 years of follow-up. We report the emergence of memory and polyfunctional CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T lymphocytes sensitized to the transgene soon after the start of therapy, and appearing in peripheral blood in waves throughout the follow-up. However, this response had no apparent impact on CNS transgene expression, which remained stable 66 months after surgery, possibly a consequence of the long-term immunosuppressive treatment. We also report that gene therapy did not trigger neuroinflammation, evaluated through the expression of cytokines and chemokines in patients\u2019 CSF. Milder disease progression in the youngest patient was found associated with low level and less differentiated circulating NAGLU-specific T cells, together with the lack of proinflammatory cytokines in the CSF. Findings in this study support a systematic and comprehensive immunomonitoring approach for understanding the impact immune reactions might have on treatment safety and efficacy of gene therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2021.655478","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T06:10:10Z","timestamp":1620627010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Marie-Lise","family":"Gougeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Poirier-Beaudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Ausseil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Z\u00e9rah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Artaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Heard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tardieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ajmg.a.33779","article-title":"Incidence and Natural History of Mucopolysaccharidosis Type III in France and Comparison With United Kingdom and Greece","author":"Heron","year":"2011","journal-title":"Am J Med Genet A"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-010-9199-y","article-title":"Mucopolysaccharidosis Type IIIB may Predominantly Present With an Attenuated Clinical Phenotype","volume":"33","author":"Valstar","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/sj.ejhg.5200242","article-title":"Sanfilippo Type B Syndrome (Mucopolysaccharidosis III B): Allelic Heterogeneity Corresponds to the Wide Spectrum of Clinical Phenotypes","volume":"7","author":"Weber","year":"1999","journal-title":"Eur J Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217819","article-title":"Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches","volume":"21","author":"Beneto","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R047175","article-title":"Gene Therapy for the Neurological Manifestations in Lysosomal Storage Disorders","volume":"55","author":"Cheng","year":"2014","journal-title":"J Lipid Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/v12040460","article-title":"Battling Neurodegenerative Diseases With Adeno-Associated Virus-Based Approaches","volume":"12","author":"Mijanovic","year":"2020","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human SGSH and SUMF1 cDNAs in Children With Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I\/II Trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3558-04.2004","article-title":"Improved Behavior and Neuropathology in the Mouse Model of Sanfilippo Type IIIB Disease After Adeno-Associated Virus-Mediated Gene Transfer in the Striatum","volume":"24","author":"Cressant","year":"2004","journal-title":"J Neurosci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66778","article-title":"Whole Body Correction of Mucopolysaccharidosis IIIA by Intracerebrospinal Fluid Gene Therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1023\/a:1025177411938","article-title":"A Model of Mucopolysaccharidosis IIIB (Sanfilippo Syndrome Type IIIB): N-acetyl-alpha-D-glucosaminidase Deficiency in Schipperke Dogs","volume":"26","author":"Ellinwood","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.265","article-title":"Safe, Efficient, and Reproducible Gene Therapy of the Brain in the Dog Models of Sanfilippo and Hurler Syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.169","article-title":"Immune Responses to Intramuscular Administration of Alipogene Tiparvovec (AAV1-LPL(S447X)) in a Phase II Clinical Trial of Lipoprotein Lipase Deficiency Gene Therapy","volume":"25","author":"Ferreira","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358","article-title":"Successful Transduction of Liver in Hemophilia by AAV-Factor IX and Limitations Imposed by the Host Immune Response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.172","article-title":"Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials With Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy","volume":"28","author":"Ertl","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.885","article-title":"Immune Responses to AAV in a Phase I Study for Canavan Disease","volume":"8","author":"McPhee","year":"2006","journal-title":"J Gene Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20870","article-title":"Gene Therapy of the Brain in the Dog Model of Hurler\u2019s Syndrome","volume":"60","author":"Ciron","year":"2006","journal-title":"Ann Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58644","article-title":"Innate Immunity in the Central Nervous System","volume":"122","author":"Ransohoff","year":"2012","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome: An Uncontrolled Phase 1\/2 Clinical Trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0022-1759(02)00072-8","article-title":"Multiparametric Flow Cytometric Analysis of Biochemical and Functional Events Associated With Apoptosis and Oncosis Using the 7-Aminoactinomycin D Assay","volume":"265","author":"Lecoeur","year":"2002","journal-title":"J Immunol Methods"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22520","article-title":"Lymphocytes Subsets Reference Values in Childhood","volume":"87","author":"Tosato","year":"2015","journal-title":"Cytometry A"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119873","article-title":"Following the Fate of Individual T Cells Throughout Activation and Clonal Expansion. Signals From T Cell Receptor and CD28 Differentially Regulate the Induction and Duration of a Proliferative Response","volume":"100","author":"Wells","year":"1997","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0128714","DOI":"10.1371\/journal.pone.0128714","article-title":"Pathogen-Specific T Cell Polyfunctionality is a Correlate of T Cell Efficacy and Immune Protection","volume":"10","author":"Boyd","year":"2015","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052246","article-title":"Acquisition of Direct Antiviral Effector Functions by CMV-specific CD4+ T Lymphocytes With Cellular Maturation","volume":"203","author":"Casazza","year":"2006","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838336","article-title":"Polyfunctional HCV-specific T-Cell Responses are Associated With Effective Control of HCV Replication","volume":"38","author":"Ciuffreda","year":"2008","journal-title":"Eur J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/srep00216","article-title":"Multifunctional CD4 T Cell Responses in Patients With Active Tuberculosis","volume":"2","author":"Qiu","year":"2012","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10020119","article-title":"Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases","volume":"10","author":"Perez","year":"2020","journal-title":"Brain Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2012.0132","article-title":"Pediatric Reference Ranges for Proinflammatory and Anti-Inflammatory Cytokines in Cerebrospinal Fluid and Serum by Multiplexed Immunoassay","volume":"33","author":"Pranzatelli","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-306647","article-title":"CD8(+) T-cell Responses to Adeno-Associated Virus Capsid in Humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuron.2019.03.020","article-title":"Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality","volume":"102","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV Capsid to Evade Immune Responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD Gene for Parkinson\u2019s Disease: An Open Label, Phase I Trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene Delivery of AAV2-neurturin for Parkinson\u2019s Disease: A Double-Blind, Randomised, Controlled Trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and Tolerability of Putaminal AADC Gene Therapy for Parkinson Disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nm1549","article-title":"Immune Responses to AAV Vectors: Overcoming Barriers to Successful Gene Therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI34676","article-title":"Immune Tolerance Improves the Efficacy of Enzyme Replacement Therapy in Canine Mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1086\/522236","article-title":"Enhanced Response to Enzyme Replacement Therapy in Pompe Disease After the Induction of Immune Tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am J Hum Genet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant Human Acid [Alpha]-Glucosidase: Major Clinical Benefits in Infantile-Onset Pompe Disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/TACG.S57682","article-title":"Recent Advances in Gene Therapy for Lysosomal Storage Disorders","volume":"8","author":"Rastall","year":"2015","journal-title":"Appl Clin Genet"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s1079-9796(03)00012-3","article-title":"Enzyme Therapy of Gaucher Disease: Clinical and Biochemical Changes During Production of and Tolerization for Neutralizing Antibodies","volume":"30","author":"Zhao","year":"2003","journal-title":"Blood Cells Mol Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2007.07.010","article-title":"Immunology of Neurological Gene Therapy: How T Cells Modulate Viral Vector-Mediated Therapeutic Transgene Expression Through Immunological Synapses","volume":"4","author":"Lowenstein","year":"2007","journal-title":"Neurotherapeutics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin Immunity in Duchenne\u2019s Muscular Dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617726114","article-title":"Class I-restricted T-Cell Responses to a Polymorphic Peptide in a Gene Therapy Clinical Trial for alpha-1-antitrypsin Deficiency","volume":"114","author":"Calcedo","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0847","article-title":"Induction of Antigen-Specific CD4+ T-Cell Anergy and Deletion by In Vivo Viral Gene Transfer","volume":"104","author":"Dobrzynski","year":"2004","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.02.014","article-title":"The Balance Between CD8(+) T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance is Dependent on the Vector Dose","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.omtm.2019.08.012","article-title":"Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle","volume":"15","author":"Poupiot","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.33","article-title":"Nonredundant Roles of IL-10 and TGF-beta in Suppression of Immune Responses to Hepatic AAV-factor IX Gene Transfer","volume":"19","author":"Hoffman","year":"2011","journal-title":"Mol Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70314","article-title":"Human Treg Responses Allow Sustained Recombinant Adeno-Associated Virus-Mediated Transgene Expression","volume":"123","author":"Mueller","year":"2013","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag2590","article-title":"How Neuroinflammation Contributes to Neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00018","article-title":"The Role of Markers of Inflammation in Traumatic Brain Injury","volume":"4","author":"Woodcock","year":"2013","journal-title":"Front Neurol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020344","article-title":"Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease","volume":"9","author":"Heon-Roberts","year":"2020","journal-title":"J Clin Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.252784899","article-title":"Activated Microglia in Cortex of Mouse Models of Mucopolysaccharidoses I and IIIB","volume":"100","author":"Ohmi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.21912","article-title":"Innate and Adaptive Immune Activation in the Brain of MPS IIIB Mouse Model","volume":"87","author":"DiRosario","year":"2009","journal-title":"J Neurosci Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e2296","DOI":"10.1371\/journal.pone.0002296","article-title":"Early Neurodegeneration Progresses Independently of Microglial Activation by Heparan Sulfate in the Brain of Mucopolysaccharidosis IIIB Mice","volume":"3","author":"Ausseil","year":"2008","journal-title":"PLoS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.655478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T06:10:14Z","timestamp":1620627014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.655478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2021.655478"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.655478","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"article-number":"655478"}}